Edited Transcript of FATE earnings conference call or presentation 5-Nov-19 10:00pm GMT [Yahoo! Finance News]
Fate Therapeutics, Inc. (FATE)
Last fate therapeutics, inc. earnings: 3/2 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.fatetherapeutics.com/investor-relations
Company Research
Source: Yahoo! Finance News
Joining me on today's call are Dr. Dan Shoemaker, our Chief Scientific Officer; Dr. Bob Valamehr, our Chief Development Officer and Dr. Wayne Chu, our Vice President of Clinical Development. Over the past 3 months, Fate Therapeutics has achieved a series of key milestones that have firmly established the company as the leading manufacturer and developer of off-the-shelf engineered NK-cell and T-cell cancer immunotherapy and which enable the company to generate decisive clinical data across multiple product candidates from our iPSC product platform. These milestones include, one, treatment of the first patient with FT516. FT516 is an off-the-shelf targeted NK-cell cancer immunotherapy derived from a clonal master-induced pluripotent stem cell or iPSC line engineered to uniformly express a novel, high affinity, noncleavable, CD16 Fc receptor. FT516 is the second product candidate emerging from our iPSC product platform and it is the first ever cell product in the world derived from a ge
Show less
Read more
Impact Snapshot
Event Time:
FATE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FATE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FATE alerts
High impacting Fate Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FATE
News
- Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates [Yahoo! Finance]Yahoo! Finance
- Fate Therapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]Yahoo! Finance
- Fate Therapeutics, Inc. (NASDAQ: FATE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Fate Therapeutics, Inc. (NASDAQ: FATE) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.MarketBeat
- Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business UpdatesGlobeNewswire
FATE
Earnings
- 11/12/24 - Beat
FATE
Sec Filings
- 11/14/24 - Form SC
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- FATE's page on the SEC website